tiprankstipranks
Trending News
More News >
General Cannabis Corp (CANN)
OTHER OTC:CANN

General Cannabis (CANN) AI Stock Analysis

Compare
519 Followers

Top Page

CA

General Cannabis

(OTC:CANN)

37Underperform
General Cannabis's stock is rated at the lowest end of the scale at 37 due to severe financial challenges, including negative profitability and cash flows, compounded by technical indicators pointing to a continued bearish trend. The lack of profitability or dividend yield further diminishes the stock's valuation appeal. The neutral earnings call impact does not offset these negative factors.

General Cannabis (CANN) vs. S&P 500 (SPY)

General Cannabis Business Overview & Revenue Model

Company DescriptionTrees Corporation provides products and services to the regulated cannabis industry and non-cannabis customers in the United States. The company operates through Retail and Cultivation segments. It operates a licensed 17,000 square foot light deprivation greenhouse cultivation facility; and a retail dispensary store in Englewood, Colorado, as well as two retail stores in Portland, Oregon. The company was formerly known as General Cannabis Corp. and changed its name to Trees Corporation in June 2022. Trees Corporation was incorporated in 2013 and is headquartered in Denver, Colorado.
How the Company Makes MoneyGeneral Cannabis Corp makes money through a diversified revenue model primarily centered around the cannabis industry. The company generates revenue by providing consulting services that help cannabis businesses navigate complex regulatory landscapes and optimize their operations. Another significant revenue stream is security services, which include offering specialized protection and surveillance solutions tailored to the unique needs of cannabis enterprises. Additionally, General Cannabis earns income through its real estate division, which involves leasing and selling properties designed for cannabis cultivation, processing, and retail distribution. The company also benefits from strategic partnerships and acquisitions that enhance its service offerings and expand its market reach.

General Cannabis Financial Statement Overview

Summary
General Cannabis faces significant financial challenges, as seen in declining revenues, negative profitability margins, and a precarious financial position with negative equity. The high reliance on debt and negative cash flows highlight liquidity and solvency risks. Improvement efforts should focus on cost control and revenue enhancement to stabilize the financial trajectory.
Income Statement
35
Negative
The company has shown a declining revenue trend with a negative revenue growth rate from the previous year to TTM. Gross profit margin for TTM is approximately 38.7%, which indicates a reasonable ability to cover direct costs. However, the net profit margin remains negative due to substantial net losses, reflecting ongoing challenges in achieving profitability. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.
Balance Sheet
25
Negative
The balance sheet indicates a concerning financial position with negative stockholders' equity in the TTM, suggesting insolvency risk. The debt-to-equity ratio is not meaningful due to negative equity, and ROE is negative, indicating unprofitable equity deployment. The equity ratio is also negative, underscoring a heavy reliance on debt financing, which could pose significant financial risks.
Cash Flow
30
Negative
The operating cash flow is negative, and free cash flow remains negative, showing a challenging cash flow situation. The free cash flow growth rate has improved from the previous year, yet remains negative. The ratios of operating and free cash flow to net income are not favorable, indicating difficulties in converting income to cash.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
11.37M18.14M13.44M5.93M7.12M3.67M
Gross Profit
4.18M6.57M4.87M1.49M1.65M1.20M
EBIT
-1.54M-3.97M-3.17M-3.01M-6.07M-8.86M
EBITDA
-3.68M-1.64M-5.37M-6.12M-6.19M-11.33M
Net Income Common Stockholders
-6.95M-7.08M-9.48M-10.31M-8.53M-14.83M
Balance SheetCash, Cash Equivalents and Short-Term Investments
7.96M969.68K2.58M2.05M750.22K122.39K
Total Assets
10.74M23.25M31.69M22.02M8.52M3.50M
Total Debt
5.27M17.88M22.54M10.15M4.76M2.33M
Net Debt
-2.68M16.91M19.96M8.10M4.01M2.21M
Total Liabilities
6.19M23.10M25.29M12.42M7.52M6.25M
Stockholders Equity
4.55M148.16K6.41M9.61M1.00M-2.74M
Cash FlowFree Cash Flow
-216.65K-1.43M-2.11M-2.98M-5.32M-5.65M
Operating Cash Flow
-198.41K-1.13M-2.05M-2.65M-5.00M-5.33M
Investing Cash Flow
-1.48M-304.42K-1.95M-978.74K1.11M-753.64K
Financing Cash Flow
434.33K-184.25K4.53M4.93M4.42M-1.65M

General Cannabis Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.03
Price Trends
50DMA
0.03
Negative
100DMA
0.03
Negative
200DMA
0.04
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
42.90
Neutral
STOCH
12.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANN, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.90 is Neutral, neither overbought nor oversold. The STOCH value of 12.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANN.

General Cannabis Risk Analysis

General Cannabis disclosed 33 risk factors in its most recent earnings report. General Cannabis reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

General Cannabis Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$8.33M3.29%-26.17%
52
Neutral
$5.15B3.05-44.13%2.84%16.42%-0.48%
46
Neutral
$19.56M-203.11%-41.45%40.69%
42
Neutral
$390.71M928.57-4.92%5.35%-432.51%
37
Underperform
$3.40M230.64%
31
Underperform
$23.68M-576.46%38.50%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CANN
General Cannabis
0.03
-0.07
-70.00%
DRRX
Durect
0.63
-0.41
-39.42%
AYTU
Aytu BioScience
2.13
-0.95
-30.84%
ORGO
Organogenesis Holdings
3.08
0.31
11.19%
KALA
Kala Pharmaceuticals
3.67
-2.96
-44.65%
SXTC
China SXT Pharmaceuticals
1.20
-8.48
-87.60%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.